Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against Gram-positive cocci

Teresa M. Coque, Kavindra V. Singh, Barbara E. Murray

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

The in-vitro activities of the new fluoroquinolone trovafloxacin (CP-99,219) and ciprofloxacin were determined against 225 Gram-positive cocci. Trovafloxacin was 4-32 fold more active than ciprofloxacin against staphylococci and streptococci and also showed greater activity against enterococci including vancomycin resistant Enterococcus faecium and Enterococcus faecalis that were highly resistant to aminoglycosides and/or produced β-lactamase. Trovafloxacin was also bactericidal at 3 mg/L against enterococci except for isolates for which the MICs were ≥ 2 mg/L.

Original languageEnglish (US)
Pages (from-to)1011-1016
Number of pages6
JournalJournal of Antimicrobial Chemotherapy
Volume37
Issue number5
DOIs
StatePublished - May 1996

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against Gram-positive cocci'. Together they form a unique fingerprint.

Cite this